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The primary objective of this study was to determine the role of picornavirus in flu-like episodes (temper-
ature of >38.0°C plus one respiratory and one constitutional symptom) among otherwise healthy adults
enrolled in a placebo-controlled, double-blind, randomized oseltamivir treatment study. Combined nasal and
pharyngeal swabs were collected at baseline for influenza cultures and picornavirus reverse transcription
(RT)-PCR. In addition, acute- and convalescent-serum samples were obtained for serological studies of
common respiratory pathogens. From a total of 719 subjects enrolled in the clinical trial within 36 h of the
onset of symptoms, 475 (66%) had evidence of recent influenza A or B virus infections by means of culture
and/or serological testing. Of the 244 remaining patients, 36 (15%) presented a seroconversion for at least one
of the common respiratory viruses or atypical pathogens. An RT-PCR assay for the picornavirus 5 noncoding
region (NCR) was positive in a subset of 15 (19%) of 78 patients with flu-like illnesses of undetermined etiology.
Sequence analysis of the picornavirus 5 NCR amplicons revealed that 14 (93%) of them had greater homology
to rhinoviruses, whereas 1 (7%) was related to enteroviruses. Interestingly, median total symptom scores and
oral temperatures of picornavirus-positive patients (n  15) and placebo-treated influenza virus-positive
patients (n  161) were similar over a 3-week period. We conclude that, among the influenza virus-negative
preselected cases of this study, rhinoviruses were relatively frequent pathogens associated with important
respiratory and systemic symptoms.
The Picornaviridae family, which contains single-stranded
RNA viruses, is divided into various genera such as Rhinovirus,
Enterovirus, and Hepatovirus. Rhinoviruses are the leading
cause of the common cold, a highly prevalent and benign
infection of the upper respiratory tract usually devoid of sig-
nificant systemic symptoms. However, it has been recently sug-
gested that rhinoviruses may also replicate in the tracheobron-
chial tree and may cause viral pneumonitis in selected settings
(10, 14, 23). The full scope of the disease burden associated
with rhinovirus infections has not been completely elucidated
since virus isolation is difficult and serology testing is limited by
the large number (100) of viral serotypes. The recent devel-
opment of reverse transcription (RT)-PCR assays based on
amplification of the conserved 5 noncoding region (NCR) of
picornaviruses has been shown to improve significantly the
detection of rhinoviruses in clinical samples (1, 12, 13, 25). In
the present study, we used the latter approach to determine the
role of picornaviruses in flu-like illnesses of adults enrolled in
an influenza virus neuraminidase inhibitor trial based on a
stringent clinical case definition.
(This work was presented in part at the Third International
Symposium on Respiratory Viral Infections, 1 December 2000,
St. Lucia, West Indies [abstr. P4].)
MATERIALS AND METHODS
Study population. A placebo-controlled, double-blind, randomized study of
oseltamivir (Tamiflu; Hoffmann LaRoche) was conducted during 1997 and 1998
for the treatment of influenza virus infections in otherwise healthy adults (18 to
65 years old) (20). Subjects were recruited from Canada, Hong Kong, and
Europe (Germany, Switzerland, France, United Kingdom, Norway, Finland, The
Netherlands, and Belgium) from 12 December 1997 to 18 April 1998. In that
trial, subjects were enrolled based on the presence of a flu-like illness (see below)
of 36 h duration at a time when influenza virus was circulating in their com-
munity. The clinical case definition used for enrollment was the following: fever
38°C with at least one respiratory symptom (cough, sore throat, or nasal
congestion) and at least one constitutional symptom (headache, malaise, myal-
gia, sweat or chills, or fatigue). All patients were allowed to use symptomatic
relief medication (acetaminophen) without restriction. Patients recorded their
oral temperature and their symptom score, i.e., the presence and severity of all
of the above symptoms except malaise on a four-point scale (0, absent; 1, mild;
2, moderate; 3, severe) twice daily for up to 21 days. Nasal and pharyngeal swabs
were collected at baseline and combined in the same viral transportation me-
dium. The chilled viral transportation media were shipped within 24 h to a
central laboratory where they were immediately frozen at 70°C. Acute (day 1)-
and convalescent (day 21)-serum samples were also collected for serological
testing.
Virological and serological testing for influenza virus. The presence of influ-
enza viruses was sought by culture and serology. For culture, tertiary cynomolgus
monkey kidney cells were inoculated using 300 l of nasopharyngeal swab elu-
ates collected at baseline. Influenza virus was detected by a positive hemagglu-
tination of turkey erythrocytes after a 7-day incubation period followed by hem-
agglutination inhibition (HAI) subtyping using reference ferret antisera.
Serological testing for influenza A and B virus was performed using an HAI
assay. The antigens used at the National Reference Center, Erasmus University,
Rotterdam, The Netherlands, were influenza A/Auckland/10/97 (H3N2), A/Nan-
chang/933/95 (H3N2), A/Johannesburg/82/96 (H1N1), and B/Harbin/07/94. A
seroconversion was defined by an increase of fourfold or more in HAI titers
between acute- and convalescent-serum samples.
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Serological testing for other respiratory pathogens. An exploratory examina-
tion of serum samples collected from the recruited population who did not have
evidence of recent influenza virus infection by either culture or serology was
carried out at the Erasmus University Hospital by the use of enzyme-linked
immunosorbent assays (ELISAs). For the detection of immunoglobulin A (IgA)
antibodies against respiratory syncytial virus (RSV), adenovirus, parainfluenza
type 1 (PIV-1) PIV-3, and PIV-2, an IgA capture ELISA was used essentially as
described previously for influenza A and B virus and RSV (3, 24). ELISA plates
were coated with anti-human IgA antibodies and incubated with a 1:100 dilution
of paired sera. Capture class-specific immunoglobulins were washed and then
incubated with conserved viral antigens. The quantity of bound pathogen-specific
IgA was measured following incubation with antigen-specific monoclonal anti-
bodies labelled with horseradish peroxidase. The ratio of absorbance (450 nm)
measurements of the convalescent samples to the acute samples was compared
with a predefined threshold for seroconversion to each antigen. Detection of
IgM-specific antibodies against Mycoplasma pneumoniae (Serion, Wurzburg,
Germany) and Chlamydia pneumoniae (Medac, Hamburg, Germany) was per-
formed using commercially available ELISA systems.
RT-PCR assay for picornaviruses. Presence of picornavirus RNA was sought
in a subset of randomly selected patients from European countries who tested
negative for influenza virus and other respiratory pathogens. Viral RNA was
extracted from 140 l of nasopharyngeal eluates by the use of the QIAmp Viral
RNA Mini kit (Qiagen, Mississauga, Ontario, Canada). The RNA was eluted in
50 l of Qiagen elution buffer. A one-step RT-PCR assay was developed to
amplify a fragment of approximately 400 bp within the 5 NCR of Picornaviridae.
Primers were selected from consensus regions of enterovirus and rhinovirus
sequences retrieved from GenBank (see Results). The RT-PCR protocol was
performed using the C-Therm Polymerase One-Step RT-PCR system (Boehr-
inger Mannheim, Laval, Quebec, Canada), 20 l of resuspended RNA eluate, 0.4
mM deoxynucleoside triphosphates, 20 U of RNasin (Recombinant Ribonucle-
ase Inhibitor; Promega Corporation, Madison, Wis.), 1.25% dimethyl sulfoxide,
5 mM dithiothreitol, and a 0.3 M concentration of each of the 5 (5-CAAGC
ACTTCTGTTTCCCCGG-3) and 3 (5-GAAACACGGACACCCAAAGTA-
3) primers. The cycling conditions were as follows: 30 min at 60°C and then 30 s
at 94°C, 30 s at 55°C, and 1 min at 72°C for 40 cycles, followed by a final extension
step of 2 min at 72°C. Amplified products were run on an agarose gel before
standard Southern blot hybridization with a 23-bp probe for rhinovirus (5-GG
CAGCCACGCAGGCTGGAACAC-3) labeled at its 3 end with digoxigenin
(DIG Oligonucleotide labeling kit; Boehringer Mannheim). Hybridized products
were revealed by chemiluminescence using the DIG Luminescent detection kit
(Boehringer Mannheim). The sensitivity of the RT-PCR after gel electrophoresis
and nonisotopic hybridization was estimated at 500 and 100 copies, respectively,
using an RNA standard constructed by cloning an amplified rhinovirus product
in the PCR 2.1 plasmid with the TA cloning kit (Invitrogen Corporation, San
Diego, Calif.) followed by plasmid transcription with the RNA transcription kit
(Stratagene Cloning Systems, La Jolla, Calif.). Because of the important homol-
ogy between enteroviruses and rhinoviruses within the 5NCR, positive RT-PCR
products were further analyzed by DNA sequencing using a cycle sequencing kit
(Big Dye Terminator Cycle Sequencing Ready Reaction; Perkin-Elmer Applied
Biosystems, Foster City, Calif.) and the same two PCR primers.
RESULTS
Virological and serological results. A total of 719 patients
fulfilling the clinical case definition for a flu-like syndrome of
36-h duration were enrolled in the clinical trial. An overview
of all laboratory results for the study population is outlined in
Fig. 1. Two-thirds (475 of 719) of the enrolled patients had an
influenza virus infection as confirmed by either cell culture or
serology. The overwhelming majority (91.6%) of influenza in-
fections were caused by the A/H3N2 subtype as determined
by HAI testing. Of the 244 influenza-negative subjects, 36
(14.8%) presented a seroconversion for at least one of the
FIG. 1. Overview of laboratory results in a treatment study of influenza-like illness with oseltamivir. , adenovirus (n  5), PIV (n  5), RSV
(n  5), M. pneumoniae (n  4), C. pneumoniae (n  10), mixed infections (n  7).
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common respiratory viruses or atypical pathogens. A recent
infection was confirmed for the following pathogens: adenovi-
rus (n  5), PIV-1 to -3 (n  5), RSV (n  5), M. pneumoniae
(n  4), C. pneumoniae (n  10), and mixed infections (n  7;
adenovirus-chlamydia, n  2; adenovirus-PIV, n  1; adeno-
virus-RSV, n  1; PIV-RSV, n  2; PIV-chlamydia-RSV, n 
1). Thus, the etiology of the flu-like syndrome was still un-
known for 29% (208 of 719) of the patients after influenza
cultures and routine serological assays.
Detection and identification of picornaviruses. The RT-
PCR assay for picornaviruses was performed on a subset of 78
nasopharyngeal swab eluates from randomly selected patients
with a flu-like syndrome of unknown etiology. A positive signal
was obtained after RT-PCR which was confirmed by noniso-
topic hybridization in 15 (19.2%) of the 78 patients (Fig. 2).
The sequence of the positive PCR amplicons (approximately
400 bp) was then determined in order to ascribe viruses to a
specific genus (Rhinovirus or Enterovirus). For that purpose,
the sequence of each clinical sample was aligned with eight
rhinovirus (GenBank accession numbers: a10937a, d00239a,
x02316a, af108180, af108181, af1108182, af108185, af108187)-
and eight enterovirus (GenBank accession numbers: x05690b,
x92886b, af083069b, m16560b, x67706b, x84981b, x04468b,
j02281b)-matched sequences retrieved from GenBank. A viral
sequence was tentatively ascribed to a specific genus when its
mean nucleotide homology compared to one group of control
sequences was 60% but 60% compared to the other group.
Using this classification scheme, 14 (93.3%) of the 15 viral
strains were identified as rhinoviruses due to a mean nucleo-
tide homology varying from 60.6 to 75.9% compared to the
eight rhinovirus control sequences versus a mean homology of
49.8 to 56.6% compared to the eight enterovirus control se-
quences. However, 1 (6.7%) of the 15 amplified strains gave a
faint band after overnight hybridization with the rhinovirus
probe and had mean nucleotide homologies of 66.4 and 59.0%
compared to control enterovirus and rhinovirus sequences,
respectively. Thus, on the basis of sequence analysis, this strain
was identified as probable enterovirus.
Symptom scores and oral temperatures of influenza virus-
positive and picornavirus-positive patients. Median oral tem-
peratures and total symptom scores were determined at base-
line and for up to 21 days for the 15 picornavirus-positive and
the 161 influenza virus-positive patients who received a pla-
cebo. As shown in Fig. 3, median temperature and symptom
severity curves of the picornavirus-positive patients were gen-
erally within the interquartile ranges of the influenza virus-
positive patients. However, no formal statistical analysis was
performed between the two patient groups due to the small
number of picornavirus-positive patients.
DISCUSSION
The most relevant finding of our study is the unanticipated
role of picornaviruses in the etiology of flu-like syndromes in
influenza virus-negative patients. Of a subset of influenza vi-
rus-negative patients randomly chosen, 20% were infected with
a picornavirus as determined by an RT-PCR assay for the
highly conserved viral 5 NCR (12, 13). With the availability of
recent molecular detection methods, the role of rhinoviruses in
the pathogenesis of various clinical syndromes has been ex-
panded. Once thought to be only associated with mild self-
limiting upper respiratory tract infections, rhinoviruses have
been recently linked with more serious lower airway illnesses,
including bronchitis and pneumonia (10, 14, 21). These viral
agents have also been associated with asthma and cystic fibrosis
exacerbations in children (4, 8, 15, 16). Furthermore, both in
vitro and in vivo evidence has recently indicated that rhinovi-
ruses can indeed replicate in the tracheobronchial tree (9, 23).
In line with a role of rhinoviruses in more severe clinical
syndromes, the total symptom scores and median oral temper-
atures between rhinovirus-positive and influenza virus-positive
patients were similar in our preselected cohort of patients (Fig.
3). This suggests that specific antiviral therapy directed against
rhinoviruses could be of greater clinical benefit in a subset of
patients with more-severe infections. In this regard, some an-
tiviral drugs with activity against rhinoviruses are under eval-
uation, including capsid binding agents and 3C protease inhib-
itors (17, 27). Since our subjects were preselected based on the
presence of fever and other respiratory and systemic symp-
toms, our rhinovirus-positive patients likely do not reflect the
typical rhinovirus infection. Further studies are needed to
identify the subjects at higher risk of complications and the
serotypes potentially associated with a more severe outcome as
FIG. 2. Detection of picornaviruses in nasopharyngeal swab eluates
by RT-PCR followed by chemiluminescent hybridization. The upper
panel represents the ethidium bromide-stained gel of amplified picor-
navirus products, whereas the lower panel represents the correspond-
ing hybridization with the rhinovirus probe. Lanes: 1, 100-bp ladder; 2,
blank; 3, negative nasopharyngeal sample; 4, positive nasopharyngeal
sample; 5 to 13, 50, 100, 250, 500, 1,000, 2,500, 5,000, 10,000, and
25,000 copies of a rhinovirus plasmid, respectively; 14, enterovirus
control isolate; 15, rhinovirus control isolate.
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well as the specific symptoms or signs which could be used to
differentiate rhinovirus from influenza virus infections.
The present study also provides useful information regard-
ing the use of a clinical case definition for the diagnosis of
influenza during flu outbreaks. Indeed, we found that two-
thirds of the otherwise healthy adults enrolled in a randomized
placebo-controlled study of oseltamivir (20) had a laboratory-
confirmed diagnosis of influenza by either culture or serology.
This illustrates the excellent positive predictive value of a sim-
ple case definition for influenza (fever 38°C with at least one
respiratory and one constitutional symptom) at a time when
influenza AH3N2 viruses were known to be circulating in a
community during the 1997-to-1998 winter season. Our group
(2) and others (19) have reported similar positive predictive
values for influenza virus using slightly different case defini-
tions. In these two studies, the combination of fever (above
38°C) and cough achieved the highest positive predictive value
for influenza (close to 80%). Thus, during an influenza epi-
demic, physicians can theoretically rapidly diagnose influenza
on clinical grounds in most adults with a typical flu-like syn-
drome and use this information to institute specific antiviral
therapy. However, many factors may potentially limit the use-
FIG. 3. Median oral temperatures (A) and median total symptom scores (B) over time for 15 picornavirus-positive and 161 placebo-treated
influenza virus-positive patients with influenza-like illnesses. Total symptom scores were calculated according to the presence and severity of seven
symptoms (cough, sore throat, nasal congestion, headache, myalgia, sweat or chills, and fatigue) on a four-point scale (0, absent; 1, mild; 2,
moderate; 3, severe). All patients received no antivirals but were allowed to use symptomatic relief medication (acetaminophen).
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fulness of this approach, such as the lack of an accurate sur-
veillance system with prompt diffusion of the results; the recent
use of antipyretics, which may mask the presence of fever; the
age of the patients; and the circulating viral strain(s).
No viral and/or atypical pathogens were identified in a sub-
stantial proportion of our influenza virus-negative subjects
with a flu-like episode (Fig. 1). Indeed, only 15% of the influ-
enza virus-negative subjects presented a seroconversion for
one of the common viral and/or atypical pathogens such as
adenovirus, PIV, RSV, M. pneumoniae, and C. pneumoniae.
Many reasons can explain the high percentage of undeter-
mined infections in our study. First, suboptimal nonmolecular
methods were used for the detection of most respiratory patho-
gens with the exception of picornaviruses. This may have been
of particular importance for RSV which has been previously
associated with flu-like syndromes in elderly adults (6). In that
context, multiplex RT-PCR assays for many respiratory viruses
have been recently developed and shown to be more rapid and
sensitive than traditional culture or serological assays (2, 5, 7,
11, 22, 26). Second, we did not search for other viruses (for
example, coronaviruses [18]) or bacteria that could have been
involved in the flu-like episodes of our patients. Finally, we
cannot exclude the presence of coinfections in our patients due
to the absence of comprehensive molecular testing and the
exclusion of influenza virus-positive samples for subsequent
studies.
In summary, the use of a simple case definition during an
oseltamivir clinical trial at a time when influenza was known to
be circulating in the community was associated with a high
positive predictive value for influenza in otherwise healthy
adults. Rhinoviruses were common viral pathogens among in-
fluenza virus-negative patients with flu-like syndromes, and
they were associated with a symptomatology similar to that of
influenza viruses in those preselected subjects.
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